Background Socioeconomically disadvantaged patients are at an increased risk for adverse heart failure (HF) outcomes based upon nonadherence to medications and diet. Physicians are also suboptimally adherent to prescribing evidence-based therapy for HF.
Methods Congestive Heart Failure Adherence Redesign Trial (CHART) (NCT01698242) is a multicenter, bilevel, cluster randomized behavioral efficacy trial designed to assess the impact of intervening simultaneously on physicians and their socioeconomically disadvantaged patients (annual income b$30,000) having HF with reduced ejection fraction. Treatment arm physicians received individualized feedback on their adherence to prescribing evidence-based therapy. Their patients received weekly home visits from community health workers aimed at promoting understanding of HF and integrating adherence into daily life. Control arm physicians received regular updates on advances in HF management, and patients received monthly HF educational tip sheets produced by the American Heart Association. The primary outcome was all-cause hospital days over 30 months.
Results A total of 72 physicians (treatment, 35; control, 37) and their 320 patients (treatment, 157; control, 163) were recruited within 2 years. Randomization of physicians with all of their patients being assigned to the same arm was feasible and did not compromise the comparability of patients by arm. Using 5 recruiting hospitals located within disadvantaged neighborhoods produced a cohort that was primarily African American and representative of low-income urban patients with HF with reduced ejection fraction.
Conclusion CHART will determine the value of intervening on low adherence simultaneously in physicians and their socioeconomically disadvantaged patients in reducing all-cause hospitalization days. (Am Heart J 2018; 195:139-50.) Heart failure (HF) continues to be a leading cause of hospitalizations and deaths in the United States, posing enormous burden on the health care system. The estimated annual costs of treating HF were $31 billion in 2012 and are estimated to jump to $70 billion in 2030. 1 Because these costs are primarily associated with repeated hospitalizations, the Centers for Medicare and Medicaid Services have begun penalizing hospitals with higher-than-expected readmission rates. Because underserved patients have disproportionately higher rates of HF and HF hospitalizations, 2, 3 interventions that work for this vulnerable population are needed.
Evidence-based guidelines for HF with reduced ejection fraction (HFrEF) exist, 4 but both physician adherence to recommending evidence-based therapy (EBT) and patient adherence to prescribed medications are low. Our prior study showed that when physician nonadherence to prescribing EBT was combined with patient nonadherence to prescribed medications, approximately 59% of HF patients were not getting the benefit of lifesaving therapy. 5 Suboptimal physician adherence to prescribing EBT for HF is a strong predictor of repeat hospitalizations in HF, 6 whereas physician decision support to maximize adherence can improve overall quality of HF care. 7 Suboptimal patient adherence to prescribed medications is multifactorial, including economic constraints, difficulties in navigating the health care system, inadequate knowledge of value of prescribed therapies, low motivation, depression, medication adverse effects, and stress. 8 In the particular case of underserved patients, often including racial and ethnic minorities and low-income populations, additional barriers are inadequate comprehension of the problem and difficulties in implementing treatments due to low health literacy. 9, 10 In this context, a community health worker could serve as a valuable bridge between the provider and the patient. The community health worker is a resident of the community, speaks in the same vernacular as the patient, and understands the cultural foundations upon which health information is built. 11 Benefits of interventions using community health workers as physician extenders have already been shown for chronic illnesses such as diabetes mellitus and asthma. 12, 13 However, this model has not been rigorously tested for its efficacy in the management of chronic HF in the underserved.
Our previous HF trial tested the hypothesis that self-management skills training would improve morbidity and mortality outcomes. This was a null trial, but there was a significant interaction in the prespecified income subgroups.
14 Patients with an annual income of b$30,000 showed benefit from the self-management intervention, whereas those with a higher income did not. This subgroup finding needs to be replicated in a trial specifically designed to answer the question of the efficacy of self-management skills training in the underserved with HFrEF. However, targeting the patients only, without also targeting their physicians, may be insufficient to improve outcomes. If patients are adhering to their prescribed therapies but these therapies are inconsistent with guidelines, benefit on outcomes will be attenuated.
This provided the rationale for a novel, bilevel approach to reducing repeated hospitalizations in the underserved with HFrEF by intervening simultaneously on both the patient and the provider.
Methods

Design
The Congestive Heart Failure Adherence Redesign Trial (CHART) (NCT01698242) is a multicenter, bilevel, cluster randomized behavioral efficacy trial. The trial targets both patients and their physicians simultaneously. Low-income patients with HFrEF were identified, and then their physician was recruited between May 2011 and May 2013 from 5 participating centers serving patients from disadvantaged communities in the Chicago metropolitan area. Consenting physicians were the unit of randomization, and randomization was stratified within site. Once a physician was randomized, all of his/ her subsequent patients were assigned to the same arm. This avoided contamination that could result if the patients were the unit of randomization, as the same physician could then be a participant in both the treated and control arms. Patients were the unit of analysis. To minimize any imbalance in patients across arms, no enrolled physician was allowed to have more than 12 of his/her patients enrolled in the trial. The sample size of 320 patients was required to have 80% power to detect a 45% difference between arms on the primary outcome of mean all-cause hospital days. A feasibility pilot study was conducted prior to the design and execution of this trial. 15 
Funding
The funding for the trial was provided by the National Heart, Lung, and Blood Institute through grant 1P50HL105189 to support the Rush Center for Urban Health Equity, 1 of the 5 P50 Centers for Population Health and Health Disparities funded by the National Heart, Lung, and Blood Institute to reduce population health disparities in cardiopulmonary diseases. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. Table I lists the inclusion and exclusion criteria. All low-income patients with symptomatic HFrEF hospitalized within the past 6 months for HF who were willing to participate and able to comply with the intervention regimen were considered for inclusion. Because reduced ejection fraction was not explicitly defined in the 2009 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) HF guidelines at the time of the study design, the investigators defined reduced ejection fraction as a value below the lower limit of normal of 50% based on echocardiography, radionuclide ventriculography, or cine contrast ventriculography. Only patients having HFrEF were targeted because EBT is lacking for management of patients with HF with preserved ejection fraction. Exclusion criteria were physician or patient inaccessibility or unwillingness to participate, and patients who may not be able to undergo and/or benefit from the treatment, such as likelihood of discharge to chronic care facility, cognitive dysfunction, psychological comorbidity-defined as alcohol or drug abuse or active suicidal ideation, inaccessibility for intervention sessions by virtue of having plans to move residence or lack of a fixed address, unwillingness and/or lack of interest in making behavioral changes now or in the next 6 months, monolingual in language other than English, and uncertainty of the patient's 12-month prognosis (advanced malignancy, an advance directive of "Do Not Resuscitate," patients under hospice care who would not be expected to survive beyond 12 months).
Eligibility
Recruitment
Patients and physicians were recruited from 5 medical centers in the Chicago metropolitan area. These hospitals were chosen because they serve primarily underserved populations and thus were likely to have a substantial number of eligible patients. Each recruiting hospital had a local physician in place who served as the local principal investigator of the trial. The general strategy was to identify an eligible patient, recruit the physician who treated the patient's HF condition, recruit the patient and conduct the baseline examination, and then randomize the physician. Three patient recruiting strategies were used: inpatient screening, outpatient screening at ongoing clinics, and referrals from physicians already enrolled in the trial.
Assessment protocol
The baseline and follow-up examinations at 6 and 30 months consisted of an assessment of physician-specific adherence to EBT from medical records, and a patient-specific medical examination and history, assessment of current medications, and battery of questionnaires assessing socioeconomic indicators, health behaviors, and psychosocial factors. At the conclusion of each examination, patients were asked to place a 1-month supply of a designated medication (an angiotensin converting enzyme inhibitor [ACEi] , angiotensin receptor blocker [ARB], β-blocker, or diuretic, in this order of preference, depending on which of these had been prescribed) into a bottle equipped with a pill-cap medication monitoring device (MEMS V Trackcap, AARDEX, Zug, Switzerland) and instructed to use it for the ensuing 30 days. The pill-cap monitoring device consists of a lid that holds a microchip which records the date and time when the bottle is opened. The data can then be downloaded to assess the number of times the bottle was opened as a measure of patient medication adherence.
Physician adherence to EBT was determined by identifying the prescribed medications (ACEi/ARB, β-blocker, or aldosterone antagonist) versus the indicated EBT according to current guidelines. The patients records were reviewed to assess if they had a contraindication to any class of HF medications-for ACEi/ARB: angioedema, serum creatinine N3 mg/dL, serum potassium N5 mEq/L, systolic blood pressure b80 mm Hg; for β-blocker: heart rate b45 beat/min, systolic blood pressure b80 mmHg, second-degree type 2 or third-degree atrioventricular block on electrocardiogram without a pacemaker, and history of asthma or chronic obstructive lung disease on bronchodilators; for aldosterone antagonist: serum potassium N5 mEq/L and creatinine N2 mg/dL for females or N2.5 mg/dL for males.
Hospitalizations and emergency room visits were ascertained via phone calls every 3 months. Medical records were procured. All patients' information from the records was redacted. The records then underwent an initial review by the designated trial physician (A. M.) who provided an initial determination of whether the event was possibly cardiac or clearly noncardiac. All clearly noncardiac hospitalizations (eg, orthopedic, general surgery) were adjudicated by a single adjudicator (A. M.). All possible cardiac events were sent to 2 independent physicians, from different institutions, for adjudication. In case of disagreement, the senior study cardiologist (R. D.) reviewed the record and resolved the disagreement. All adjudicators were blinded to the patients' identity and intervention arm. Duration of each hospitalization was calculated as the time difference between presentation and discharge time in days. The primary outcome of all-cause hospital days is described as the total hospital days relative to the duration of follow-up. The trial protocol was approved by the institutional review board at the central coordinating center and at each of the 5 collaborating institutions. 
Inclusion criteria
• Patient self-reported annual income b$30,000
• Patients hospitalized with decompensated HF within the last 6 m, defined as being admitted for symptoms of HF (ie, peripheral edema, shortness of breath, fatigue) and responding to HF therapy such as diuretics, β-blockers, ACEi, or ARB • Patients having HFrEF because evidence-based therapy is lacking for management of patients with HF with preserved ejection fraction. 4 HFrEF is defined by an LVEF of b50% by echocardiography, radionuclide ventriculography, or radiographic contrast ventriculography determined within 12 m preceding enrolment.
• Patient currently residing in the City of Chicago • Provider has b12 patients in the trial Exclusion criteria
• Provider unwilling to participate The interventions Figure 1 shows the hypothesized pathway by which treatment aims to benefit the primary outcome. This pathway quantifies the targets for successful implementation, the behavioral risk factor targets, and the level of hypothesized improvement in the primary outcome. The value of a hypothesized pathway lies in the interpretability of trial results. In the event of a positive trial, it will be possible to determine if the treatment worked by the hypothesized pathway (ie, all of the components were successfully implemented, improved behavioral risk factors), by a subset of the components, or by an unknown pathway (ie, none of the components). In the event of a negative trial, it will be possible to disentangle a failure of the intervention (ie, could not be implemented, did not improve behavioral risk factor targets) from a failure of the hypothesis (ie, all components were implemented and improved behavioral risk factors but no benefit on the primary outcome resulted).
A challenge for any behavioral trial is that the treatments being evaluated do not look identical, thus precluding a double-blind trial. It is possible, however, to extend the blinding in pursuit of preserving equipoise. Therefore, patients, providers, and study staff were blinded to the trial hypotheses. To further enhance blinding, neutral names were used for the trial arms. The treatment arm was called Enhanced Training, and the control arm was called Enhanced Education. The study design prevented physician crossover between study arms. Moreover, patients and participating physicians were tracked throughout the study period to protect against patient crossover between intervention and control physicians.
Patient-level treatment. Community health workers aimed to achieve 3 key learning objectives by helping patients to improve their ability to self-manage their HF by (1) understanding what HF is, what exacerbates it, and the warning signs of exacerbation; (2) understanding the function of each of their HF medications and the importance of daily adherence; and (3) learning effective strategies for identifying high-sodium foods and eating less of them in daily life. Educational materials were designed for low-health literacy patients using familiar terminology, metaphors, and tangible objects to teach HF pathogenesis and purpose of medications. For example, after-load reducers such as ACEi and ARBs were called Widening Pills. The community health workers used visuals such as a coffee stirrer and milkshake straw to demonstrate the difference between blood vessels in patients who do and do not take their medication. Reduction in sodium intake focused on reading food labels and avoidance of foods with N300 mg of sodium per serving.
Patients received 14 home visits and 28 phone calls during the 30-month trial period. The first 6 months featured monthly home visits and weekly telephone calls. Months 7 to 30 consisted of quarterly home visits and monthly phone calls to encourage maintenance of adherence. The intervention was patient tailored, allowing the community health worker to conduct additional visits, if needed. During patient follow-up visits, the community health worker asked patients for a list of their medications and dosages, which were then entered in the study database. Patient records were reviewed to assess their suitability for different classes of evidence-based heart failure therapy according to current ACCF/AHA HF guidelines.
Fidelity to the treatment was insured by specialized training and ongoing supervision of the community health workers. A 32-hour training program was facilitated by an interventionist with a master's degree, guided by a treatment manual and assisted by a cardiologist, clinical psychologist, and dietitian. The major training approach was skill development through role play. Throughout the course of the intervention, community health workers were supervised in biweekly group sessions which were led by an interventionist, a behavioral scientist, and a cardiologist, as needed. These sessions provided oversight, minimized drift or deviation from the intervention protocol, monitored safety, and used the group to solve problems and provide encouragement. Supervision sessions were enhanced with data on process measures collected by the data management team which facilitated identification of general problems and difficulties specific to individual community health workers. Treatment fidelity was monitored using strategies outlined by the National Institutes of Health Behavior Change Consortium. 16 Each home visit was digitally recorded to check adherence to the protocol and provide feedback.
Physician-level treatment. A key objective was to improve physicians' adherence to prescribing EBT for HF. This involved addressing prescription of appropriate class of HF medications at appropriate dosage based on current ACCF/AHA HF guidelines. Physicians received (1) a full and pocket-sized copy of the current ACCF/AHA HF guidelines along with updates as they became available 4, 17 ; (2) a summary of their patients' data in the trial collected during the baseline and 6-month examination; (3) a comparison between medications prescribed from the medical chart and the medications the patient reported taking; (4) an invitation to complete an 9 Self-reported items, answered as "not at all" = 0, "several days" = 1, "more than half the days" = 2, or "nearly every day" = 3, and summed to yield a score between 0 and 27. Internal consistency reliability = 0.84. Higher score indicates more severe depression. Cut point for depression is ≥10.
accredited continuing medical education online course in HF management which featured modules from the National Heart Failure Training program 18 ; (5) periodic e-mail tips on HF and HF management from the study cardiologists (R. D., J. E. C.); and (6) a personalized letter outlining a report of physician's adherence to EBT with comments from the trial cardiologist suggesting recommendations for changes. For each individual class of HF medications, if a patient was on appropriate class of HF medications with no evidence of contraindication, the letter stated, "We would like to acknowledge you for prescribing β-blocker, ACEi/ARB, and/or aldosterone antagonist in your patient where no contraindications have been identified." If there was a contraindication for a particular class of HF medication and provider did not prescribe it, the letter stated, "We would like to acknowledge you for not prescribing β-blocker, ACEi/ ARB, and/or aldosterone antagonist in your patient where a contraindication has been identified." If there was no contraindication and a patient was not prescribed a particular class of medication, the letter stated, as an example, "Your patient is not taking a β-blocker but has Class II or III heart failure without a contraindication. Would you consider prescribing a β-blocker in this patient?" If a patient had a contraindication for a medication and the medication was prescribed, the letter Patient-level control. Patients in the control arm received 6 AHA educational mailings. These 1-page tip sheets were sent monthly during the first 6 months to align with the monthly visits from the community health workers in the treatment arm. The tip sheets provided HF education, summarizing basic elements of patient-level HF management including medication adherence, sudden weight gain, sodium restriction, moderate physical activity, and stress management. The trial tracked the number of educational mailings sent and contacted the patient by phone if the mail was returned to obtain a corrected address for mailing.
Physician-level control. Physicians in the control arm received a copy of the current ACCF/AHA HF guidelines along with any update to these guidelines as they became available.
Outcomes
A selected list of outcome assessments is presented in Table II . The primary outcome was all-cause hospitalization days over the 2.5-year follow-up period. This outcome was chosen because HF morbidity and cost are largely driven by total burden of hospitalization and not the mere incidence of a hospitalization. In fact, hospitalization days have tripled in HF patients in the last few decades, resulting in increased demands on clinical practice, excessive costs, loss of productivity, and increased attention in clinical research. 1, [19] [20] [21] [22] [23] Furthermore, because HF is a disease with systemic ramifications (higher risk for infection, renal failure, stroke, etc), the total all-cause hospital days, rather than HF hospital days, were selected as an outcome to account for the global impact of HF on overall health status. Heart failure hospitalizations is a secondary end point. Data safety and monitoring were conducted by an independent Data Safety and Monitoring Board (Appendix A).
Statistical considerations
The study sample size was determined to provide adequate power for a typical 2-group comparison of means (ie, mean total all-cause hospitalization days compared via t test) within a cluster-randomized design, each physician and all his/her patients representing an individual cluster. Our approach was to estimate the "design effect," an inflation factor due to clustering that is to be applied to the sample size that would have been required under an individually randomized design. Estimates of parameters required to compute the design effect were obtained from pertinent data from our Heart failure Adherence and Retention Trial 14 and resulted in an estimated mean cluster size of 10 (range, 8-12 patients per physician), with a coefficient of variation of 0.10 and an intraclass correlation coefficient (representing the correlation of responses among patients from the same physician) of 0.05. We further assumed 80% power to detect a 45% reduction in observed mean all-cause hospitalization days in the intervention group relative to the control group. The resulting sample size was then further inflated by 15% to account for potential attrition due to withdrawals and being lost to follow-up, resulting in a final sample size of 320 participants (160 per group). Mixed-effects modeling assuming a negative binomial distribution and physician cluster as a random effect will be used as a companion analysis. 25, 26 These generalized linear models accommodate potentially overdispersed count data within a clustered trial design and allow control for important covariates that may have an independent impact on the outcome, such as age, gender, ethnicity, primary care physician specialty, and duration of follow-up (time on study). Generally, continuous outcomes will be compared between groups using t tests (or the nonparametric cluster-adjusted Wilcoxon test when warranted), and categorical outcomes will be compared using adjusted χ 2 tests. These analyses will be supplemented with mixed-effects modeling to account for repeated measures (such as with sodium intake and medication adherence), clustering, and control for important covariates. In general, analyses will use an intent-to-treat strategy with missing data addressed using data imputation procedures when warranted. Figure 2 presents the consort diagram for the trial. Over 24 months, 1,989 patients were screened for HF eligibility, of which 853 (42.9%) met criteria (screening to HF eligibility ratio of 2.33). Their physicians were then screened to determine interest in the trial. Of the 101 screened, 90 (89.1%) agreed to participate, resulting in 838 HF patients who were screened for trial eligibility. Of these, 320 (38.0%) patients and 72 physicians were eligible for participation. These 72 physicians were randomized to 1 of 2 treatment arms, and all of their patients were allocated to the arm to which the physician was randomized. This resulted in the treatment arm having 35 physicians and 157 patients, and the control arm having 37 physicians and 163 patients. The screening to enrollment ratios were 1.4 for physicians and 6.22 for patients.
Results
Tables III and IV present the patient and physician baseline characteristics. Table III shows that this patient population was primarily African American (86.6%), 66.5% were below the federal poverty line, and 74.7% were less than 65 years of age. The demographics differed somewhat across the recruiting sites, resulting in a relatively representative sample when patients from all sites were combined. Physician race was at odds with that of patients. In only 5.6% of the cases was the physician African American. Most of the physicians (66.7%) were cardiologists. Approximately 50% of physicians had 1 or 2 of their patients in the trial, and 20.8% had between 10 and 12 patients. This percentage varied across recruiting sites, reflecting the different approaches to recruitment used locally. Table IV shows the balance between treatment arms on baseline characteristics. The use of the physician as the NYHA, New York Heart Association; Q1, first quartile upper limit; Q3, third quartile lower limit; PHQ-9, Patient Health Questionnaire-9 questions; BNP, B-type natriuretic peptide; CKD, chronic kidney disease; GFR, glomerular filtration rate in mL/min/1.73m 2 . ⁎ Defined as ≥80% medication adherence measured using electronic pill count counter over the course of 30 days.
† Based on PHQ-9.
unit of randomization and the restriction on the number of their patients that could be enrolled resulted in comparable characteristics by arm in both the patients and the physicians.
Discussion
CHART is 1 of the 3 flagship studies in the Rush Center for Urban Health Equity, a P50 Center supported by the National Heart, Lung, and Blood Institute's Population Health and Health Disparities Consortium. All of the centers in this consortium aim to reduce racial and ethnic disparities in cardiopulmonary diseases. HF is now accepted as a problem of racial and ethnic disparities because its costs in terms of mortality, quality of life, and repeated hospitalizations differentially affect the underserved.
2,3 CHART's focus on the underserved evolved from our prior work which raised the possibility that development of patient self-management skills to maximize adherence could differentially benefit those most vulnerable.
14 A distinct feature of CHART is its bilevel design. Although racial and ethnic disparities in health are well recognized, the reasons for these disparities are not well understood and are likely to be complex and multidimensional. 27 This has triggered an interest in multilevel interventions to improve health disparities where several factors in a complex web of causation are targeted simultaneously for the purpose of enhancing the strength of the intervention to affect clinical outcomes and its endurance. Interest in the potential of this approach has evolved more rapidly than an understanding of methods for its design and analysis. 28 Currently, there are 2 basic approaches to the design of a multilevel trial. The first aims to determine the value added by intervening on more than 1 level by examining the independent and synergistic effects of different levels using some type of factorial design. 29 The second is less concerned with dismantling and more concerned with efficacy compared with a clinically relevant control. 30, 31 The challenge in this latter type of design is in identifying a unit of randomization that does not compromise the unit of analysis. If, for example, improvement in a patient-level outcome is the goal and treatment is aimed at patients and physicians embedded in clinics, randomization of clinics with clustering at both the physician and clinic level is the best way to avoid contamination of treatment. 32 This, however, makes demands on power and sample size.
This was the problem faced in CHART where the goal was to intervene simultaneously on patients and their physicians. The rationale for intervening on these 2 levels was that if adherence could not be improved on both the physician and patient levels, the benefit on HF hospitalization would be undercut. The unit of analysis was the patient. But if the patient was also the unit of randomization, their physicians could easily end up being in both treatment arms, depending upon the arm to which their patients were randomized. This problem was solved by making physicians the unit of randomization and requiring that all of their eligible patients be randomized to the same arm as their physicians. This could, however, create a problem for the unit of analysis. Because the primary outcome was patient hospital days, it was crucial to ensure that there was comparability between arms on patient characteristics. This was accomplished by capping the number of patients enrolled with any randomized physician at 12. Because only 20.8% of the physicians in the trial enrolled between 10 and 12 patients and 50% enrolled between 1 and 2 patients, the comparability on patient characteristics between the treatment arms was protected.
Because the target population was a vulnerable one, attention to cultural sensitivity was essential in 2 important areas: "why" patients should adhere to treatment recommendations and "how" they could embed adherence into their daily lifestyles. On the "why" side, we used a multidisciplinary team comprised of a behavioral scientist, a cardiologist, a health educator, and a community representative to develop educational materials that avoided unnecessarily complex medical jargon and relied instead upon familiar metaphors, visuals, and terminology to explain the pathogenesis of HF and the rationale for drug treatment and salt restriction. On the "how" side, community health workers went into patients' homes and tailored treatment recommendations to existing routines. They did this by first developing a relationship with the patient and then directing discussions toward management of HF.
Cultural sensitivity was important on the physician side of the intervention as well. The culture within which most physicians operate is burdened by tight schedules, limited time, and increasing demands for reporting. In such a time-urgent setting, it is a challenge to find ways to provide education about evidence-based HF therapy. Above and beyond the ACCF/AHA practice guidelines and updates received in both arms, there were several options for physicians in the treated arm. An internet-based module on HF management was available for continuing education credit, but it had a limited uptake. More successful was using trial data to provide feedback to the physician on his/her patient which included the results of laboratory tests and discrepancies in prescribed medications documented in the medical chart and reported by the patient. This report was accompanied by feedback from the trial cardiologists (J. E. C., R. D.) which reinforced prescribing practices when they were consistent with guidelines and made suggestions when they were not. This communication channel appeared to be distinctive and efficient enough to promote uptake and potentially influence decision making.
A limitation of this trial, consistent with all behavioral trials, is that double blinding was impossible given that the nature of the treatments is obvious to all. It is, however, possible to extend the blinding in as many ways as possible. In CHART, patients and staff were blinded to trial hypothesis, and neutral names were given to the trial arms. The treated group was referred to as Enhanced Training, and the control was referred to as Enhanced Education. All investigators and staff, except for the senior trial biostatisticians working in the independent Data Management Center, were blinded to the randomization status of the physician and their patients. Treatment teams in one arm had no contact with staff or patients in the other arm.
A second limitation is that the CHART design is not a dismantling design and will not allow an independent assessment of the value of each level individually and synergistically on the primary outcome. The existence of a hypothesized pathway, however, will make it possible to determine whether or not each level of the intervention was implemented as planned and achieved its hypothesized benefit on the behavioral risk factor target of the intervention. This information will make it possible to interpret the results on the primary outcome based upon success in accomplishing each of the 2 levels of the treatment and to determine whether or not a future dismantling trial would be worthwhile.
A third limitation is the targeting of our intervention on a reduction in sodium intake, in light of emerging data which question the beneficial impact of reducing sodium intake in HF patients. 33 The current guidelines continue to recommend sodium restriction in HF patients, but the class of this recommendation has been downgraded in serial guidelines. Thus, there is a possibility that even if the intervention achieves the target of reducing sodium intake, it may not translate into an improved primary outcome. Moreover, since the inception of the trial, emerging data and practice guidelines have emphasized the benefit of physical activity, 4, 34, 35 a behavioral factor that was not primarily targeted in the present trial.
Because this was a multicenter trial involving both community and university hospitals, there was a risk of sicker patients from higher-acuity centers being overly represented in one of the trial arms and undercutting the balance otherwise achieved by randomization. However, this was not a problem because randomization was stratified within site, resulting in no significant differences in patient characteristics across the trial arms.
In summary, HF is among the costliest of chronic diseases. The seriousness of this disease is exacerbated by its differential prevalence in those who are most vulnerable. This trial provided new resources to both the patient and the provider that are currently not a part of our overburdened medical care system. The results from CHART will determine whether or not these additional resources can be justified by a reduction in costs and an improvement in quality of life.
Appendix. Data and Safety Monitoring Board
